Compare Bank of Nova Scotia (BNS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Johnson & Johnson — how do they compare? Bank of Nova Scotia trades at $89.97 (market cap $108.32B), while Johnson & Johnson trades at $260.25 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 5.8× Bank of Nova Scotia's market cap, and Bank of Nova Scotia pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| BNS | JNJ | |
|---|---|---|
Market Cap | $108.32B | $626.09B |
Sector | Financials | Health |
52-Week High | $90.29 | $267.24 |
52-Week Low | $56.41 | $172.78 |
Dividend Yield | 3.64% | 2.06% |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $89.92, up 1.54% with a bullish technical outlook supported by moving averages. The company demonstrates consistent earnings growth, beating estimates for three consecutive quarters with Q2 2026 expected at $1.53 EPS. Recent acquisition of MapleMark Bank and dividend increase to $1.14 highlight strategic growth initiatives. Valuation metrics show a P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a favorable investment case with analyst consensus leaning bullish (53% buy ratings) and technical indicators supporting upward momentum. Key opportunities include dividend growth, international expansion, and improving ROE at 11.87%. Risks include macroeconomic sensitivity, declining profit margins from 31.47% in 2022 to 20.99% in 2025, and elevated debt levels with $194.31 billion long-term obligations.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
